(Duaklir ® Genuair ®, Ultibro ® Breezhaler ®, Inspiolto ® Respimat ®, Anoro ® Ellipta ®) (Onbrez ® Breezhaler ®, Serevent ® Diskus ®) (Tudorza ® Genuair ®, Seebri ® Breezhaler ®, Spiriva ® Handihaler ®) (Incruse ® Ellipta ®, Spiriva ® Respimat ®) (Ventolin ®, Airomir™, Bricanyl ® Turbuhaler ®) History of ≥ 1 severe exacerbation defined as requiring a hospital admission or emergency department visit in the previous 12 months.ĤHistory of exacerbations is defined as follows:Ĭurrent coverage will be maintained for patients currently covered for COPD inhalers through PharmaCare, though some will have the option to switch.History of ≥ 2 moderate exacerbations defined as requiring a prescribed antibiotic and/or using systemic glucocorticoids in the previous 12 months or.Very severe COPD is defined as FEV1 Severe COPD is defined as 30% Moderate COPD is defined as 50% List Trelegy Ellipta, the new triple therapy fixed-dose combination (i.e., ICS-LABA-LAMA), as a limited coverage benefit for moderate-to-very-severe patients with COPD diagnosed by spirometry, history of exacerbations 4, with a 6-month trial of either a LAMA-LABA combination or an ICS-LABA combinationġThe spirometry requirement for the diagnosis of moderate-to-very-severe COPD requires a post-bronchodilator fixed ratio of FEV1/forced vital capacity (FVC) Modify criteria for inhaled corticosteroids (ICS)-LABA combination inhalers to include diagnosis for moderate-to-very-severe COPD by spirometry, history of exacerbations 3, and a 6-month trial of either a LAMA or a LABA.Increase access to LAMA-LABA combination therapies for moderate to very severe 2 patients with COPD by expanding the current forced expiratory volume in 1 second (FEV 1) threshold requirement from Modify criteria for long-acting beta 2 agonists (LABA) to include diagnosis 1 of COPD by spirometry and contraindications or intolerance to a LAMA.Continue coverage for other LAMAs (Tudorza ® Genuair ®, Spiriva ® Handihaler ®, Seebri ® Breezhaler ®) as limited coverage benefits with changes in criteria: failure on a minimum one-month trial of each of the regular benefit LAMA products.Improve access to long-acting muscarinic antagonists (LAMA) by moving tiotropium (Spiriva ® Respimat ®) and umeclidinium (Incruse ® Ellipta ®) from limited coverage benefits to regular benefit coverage.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |